In this issue of JAMA Internal Medicine, a report by Li et al1 from a large population-based case-control study suggests that long-term use of calcium-channel blockers (CCBs) is associated with a greater than 2-fold increase in the risk of breast cancer in postmenopausal women. This is not the first time that the specter of CCB-associated cancer has arisen: in 1996, Pahor et al2 reported a statistically significant 72% increase in risk of all cancers among CCB users in an elderly cohort, including a nonsignificant 65% increased risk of breast cancer. This was followed in 1997 by a report from another elderly cohort of a statistically significant relative risk (RR) for breast cancer of 2.6 among ever users of CCBs.3 Both studies were based on small numbers. Subsequent larger case-control and cohort studies failed to confirm the CCB-cancer association for all cancers4 or for breast cancer,5 nor did excess cancers occur in up to 5 years of follow-up in 3 randomized clinical trials of CCBs.6- 8 The CCB-cancer hypothesis went into hibernation.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.